News
Vertex’s Kalydeco obtains FDA approval to treat CF in...
Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in children aged...
News
PARP inhibitors effective against cancer cells with fault CBLC...
Researchers at London's Institute of Cancer Research (ICR) have found that cancer cells with a fault in the protein-coding CBLC gene could be sensitive to...
News
Actavis acquires Botox-maker Allergan for $70.5bn
Actavis has completed the acquisition of US-based Botox-maker Allergan, in a deal valued around $70.5bn. With combined annual pro forma revenues of...
News
Lilly Provides Update on Evacetrapib Phase 3 Trial
INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on...
News
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials H1 2015...
The clinical trial report “Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015” provides data on the Keratoconjunctivitis sicca (Dry Eye) clinical trial scenario....
News
Precision for Value Expands Health Economics and Outcomes Research...
February 19, 2015, New York – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company, which provides health economics, analytics, and marketing communications services to...
News
Exelixis Announces Acceptance of New Drug Application for Cobimetinib...
FDA Grants Priority Review, Assigns Action Date of August 11, 2015 - SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NASDAQ:EXEL) announced today that the U.S....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.